Comparing Contrast-Enhanced Ultrasound and Abbreviated MRI for Early Detection of Liver Cancer in Adults with Unclear Liver Nodules

What this Trial Is About

Researchers are evaluating and comparing two imaging tests, contrast-enhanced ultrasound CEUS and abbreviated MRI AMRI, for early detection of liver cancer called hepatocellular carcinoma HCC in adults with indeterminate liver nodules. This study focuses on patients with Child A or B cirrhosis who have liver nodules that are unclear but do not have confirmed HCC at the start. The purpose is to determine which imaging method better detects early-stage HCC to guide patient care. Participants will undergo both CEUS and AMRI tests every 3 to 6 months. For patients with LR3 nodules, these tests will be done every 6 months, while those with LR4 nodules will have tests 3 months after enrollment and then every 6 months. The imaging procedures are preferably performed on the same day to reduce inconvenience but can be done within up to 14 days of each other. Follow-up continues for up to 24 months or until the nodules change to definitely or likely benign or HCC develops. During the study, participants will be monitored with these imaging tests regularly to track changes in liver nodules. Researchers will measure early detection of HCC as the main outcome over a 5-year period. The study includes detailed imaging assessments and aims to identify the best method for surveillance. Participants will be followed for up to two years with imaging at scheduled intervals and will not undergo any treatment as part of this trial.

CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules